No clear evidence that most new cancer drugs enhance life
Most cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence they improved survival or quality of life. Even where drugs did show patient survival gains over existing treatments, these were often marginal, a study found.
32, 9, 16-16.
Want to read more?
Already subscribed? Log in
Unlock full access to RCNi Plus today
Save over 50% on your first 3 months
Your subscription package includes:
- Unlimited online access to all 10 RCNi Journals and their archives
- Customisable dashboard featuring 200+ topics
- RCNi Learning featuring 180+ RCN accredited learning modules
- RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
Alternatively, you can purchase access to this article for the next seven days. Buy now